FTSE MIB
34.267,17 -96,58 (-0,28%) Dow Jones
38.420,34 -83,35 (-0,22%) Nasdaq
15.747,58 +50,94 (+0,32%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
83,01 -0,35 (-0,42%) Bitcoin EUR
60.798,52 -1.844,91 (-2,95%)
Genprex, Inc. (0A8I.L)
| Chiusura precedente | 2,8850 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 2.261 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | -0,63 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3950 |
| Prossima data utili | 22 mag 2024 - 26 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation,” please visit: https://nnw.fm/619wq More than 30 million pe
GlobeNewswireIBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc.
LOS ANGELES, July 06, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel
